HBV and HBsAg strongly reshape the phenotype, function, and metabolism of DCs according to patients’ clinical stage by Lucile Dumolard, Theophile Gerster, Florent Chuffart, Thomas Decaens, Marie-Noelle Hilleret, Sylvie Larrat, Philippe Saas, Evelyne Jouvin-Marche, David Durantel, Patrice N. Marche, Zuzana Macek Jilkova, Caroline Aspord

“…Infected individuals who fail to control the viral infection develop chronic hepatitis B and are at risk of developing life-threatening liver diseases, such as cirrhosis or liver cancer. Dendritic cells (DCs) play important roles in the immune response against HBV but are functionally impaired in patients with chronic hepatitis B. …”
Get full text

Gene Ontology and Expression Studies of Strigolactone Analogues on a Hepatocellular Carcinoma Cell Line by Mohammed Nihal Hasan, Syed Shoeb Razvi, Hani Choudhry, Mohammed A. Hassan, Said Salama Moselhy, Taha Abduallah Kumosani, Mazin A. Zamzami, Khalid Omer Abualnaja, Majed A. Halwani, Abdulrahman Labeed Al-Malki, Jiannis Ragoussis, Wei Wu, Christian Bronner, Tadao Asami, Mahmoud Alhosin

“…Human hepatocellular carcinoma (HCC) is the most common and recurrent type of primary adult liver cancer without any effective therapy. Plant-derived compounds acting as anticancer agents can induce apoptosis by targeting several signaling pathways. …”
Get full text

Cancer mortality and sectors of employment: a cohort study in Italy by Stefania Massari, Lisa Bauleo, Claudio Gariazzo, Paola Michelozzi, Luca Dei Bardi, Nicolas Zengarini, Sara Maio, Massimo Stafoggia, Marina Davoli, Giovanni Viegi, Giulia Cesaroni, Alessandro Marinaccio, on behalf of the BIGEPI Collaborative Group

“…Among women, there was an elevated mortality risk in the cleaning industry for all malignant cancers (HR = 1.15, 95% CI:1.03–1.29), liver cancer (HR = 1.94, 95% CI:1.08–3.48) and cancer of the lympho-hematopoietic tissue (HR = 1.65, 95% CI:1.09–2.50). …”
Get full text

Mitochondrial dysfunction-driven AMPK-p53 axis activation underpins the anti-hepatocellular carcinoma effects of sulfane sulfur by Xue Zheng, Yuhua Luo, Rui Huo, Yiwen Wang, Youbang Chen, Mianrong Chen, Qi Zhao, Kexin Li, Hanyi Zhang, Xiaotong Li, Xiang Li, Hui Zhang, Zaopeng He, Li Huang, Chun-tao Yang

“…Abstract Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, notoriously refractory to conventional chemotherapy. …”
Get full text

Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy by Hafiza Kashaf Tariq, Zihao Liang, Lawan Rabiu, Abdulrahman Ibrahim, Nada Mohamady Farouk Abdalsalam, Rong Li, Qiong Yang, Xiaochun Wan, Dehong Yan

“…Recent research suggests that an MDSC blockade can unleash the full therapeutic potential of the combined therapy of ferroptosis and ICB in liver cancer treatment. However, whether blocking the intrinsic ferroptosis pathways of MDSCs can relieve imidazole ketone erastin (IKE)-initiated ferroptosis-induced immune suppression and ultimately trigger the optimal therapeutic effect of the combined ferroptosis and ICB therapy is still unknown. …”
Get full text

Simultaneous Liver Venous Deprivation Following Hepatic Arterial Chemoembolization Before Major Hepatectomy for Hepatocellular Carcinoma: A New Methods to Achieve Hypertrophy Liver... by Zhang S, Song R, Hou C, Yao H, Xu J, Zhou H, Li S, Cai W, Fei Y, Meng F, Yin D, Wang J, Zhang S, Liu Y, Wang J, Liu L

“…The modified response evaluation criteria for solid tumor assessment revealed a disease control rate of 95.7%, with only 1 patient (Barcelona Clinic Liver Cancer stage C) developing intrahepatic disease progression.Conclusion: TACE-LVD seems to be a feasible, safe, and effective strategy for rapid FLR hypertrophy. …”
Get full text

Management of Diabetes Mellitus in Patients with Chronic Liver Diseases by Yingying Zhao, Huichun Xing, Xiaomei Wang, Weini Ou, Hong Zhao, Ben Li, Yue Li, Ying Duan, Liwei Zhuang, Wei Li, Danying Cheng, Min Quan, Yu Zhang, Shibo Ji

“…According to a growing body of research, diabetes shows a close correlation with hepatitis, liver cirrhosis, and liver cancer. Moreover, coexistence of liver complications would accelerate the deterioration of patients with diabetes. …”
Get full text

Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents by Zhang Y, Xia H, Fan L, Jiang L, Yang B, Wang F

“…Yaping Zhang,1,2,* Huan Xia,3,* Luchang Fan,1 Lu Jiang,4 Bin Yang,2 Fengmei Wang4,5 1The Third Central Clinical College of Tianjin Medical University, Tianjin Medical University, Tianjin, 300170, People’s Republic of China; 2Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Nankai University Affiliated Third Central Hospital, Tianjin, 300072, People’s Republic of China; 3Department of Infectious Diseases, Tianjin Second People’s Hospital, Tianjin, 300192, People’s Republic of China; 4Department of Hepatology and Gastroenterology, Tianjin First Central Hospital, Tianjin, 300192, People’s Republic of China; 5Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Central Hospitial, Tianjin, 300192, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fengmei Wang; Bin Yang, Email wangfengmeitj@126.com; bioyang@126.comPurpose: The research intended to present prospective data on the long-term prognosis of individuals with hepatitis C virus (HCV) infection who received direct-acting antiviral agent (DAA) treatment.Patients and Methods: Patients who received DAA treatment at Tianjin Third Central Hospital and Tianjin Second People’s Hospital were prospectively enrolled and subsequently underwent a longitudinal follow-up. …”
Get full text

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer by Jun Fan, Jing Wang, Tao Zhang, Xin Li, Lan Zhang, Zheng Wang, Tao Liu, Gang Li, Peng Zhang, Chi Ma, Ming Cai, Gang Wu, Zhenyu Lin, Kailin Cai, Xiu Nie, Junli Liu, Hongli Liu, Weikang Zhang, Jingbo Gao, Chuanqing Wu, Linfang Wang, Zhiguo Hou, Kunyu Yang, Kaixiong Tao

Get full text

Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies by Jinlin Hou, Thomas Berg, Arndt Vogel, Teerha Piratvisuth, Jörg Trojan, Enrico N. De Toni, Masatoshi Kudo, Katarina Malinowsky, Peter Findeisen, Johannes Kolja Hegel, Wenzel Schöning, Kairat Madin, Konstantin Kroeniger, Henry Lik-Yuen Chan, Ashish Sharma

“…Results: In STOP-HCC-ARP (algorithm development cohort), 1,006 patients {297 HCC (41.4% early-stage [Barcelona Clinic Liver Cancer {BCLC} 0/A) and 709 CLD} were included. …”
Get full text

Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review by Yasunori Minami, Masatoshi Kudo

“…Radiofrequency ablation (RFA) of liver cancers can be performed safely using percutaneous, laparoscopic, or open surgical techniques, and much of the impetus for the use of RFA has come from cohort series that have provided an evidence base for this technique. …”
Get full text

Extracorporeal Ultrasound-Guided High Intensity Focused Ultrasound: Implications from the Present Clinical Trials by Tinghe Yu, Xiao Fu

“…The survival rate of HIFU plus radiotherapy was lower than that of radical surgery in liver cancers. Adverse events had no downtrend in the past years. …”
Get full text

Epigenetics disruptions enabled by porphyrin-derived metal-organic frameworks disarm resistances to sonocatalytic ROS anti-tumor actions by Yan Zhang, Dou Du, Chao Fang, Xin Yu, Yujia Fang, Xinyu Liu, Di Ou, Haohao Yin, Hui Liu, Taixia Wang, Lu Lu, Xiaolong Li, Kun Zhang

“…The epigenetic deubiquitination disruption not only synergized with MOF-mediated sonocatalytic ROS production, but also inactivate deubiquitinating enzymes, blockade the deubiquitination process and further remove these resistances, both of which mutually behaved as reciprocal impetuses to significantly magnify SDT outcomes against liver cancers. Such a deubiquitination-engineered disruption approach finds an unprecedented pathway to disarm deubiquitination-induced resistances to SDT and other ROS-based anti-tumor means, which also enlightens us to establish other post-transcriptional epigenetic modification disruption strategies to re-program the tumor microenvironment and elevate the anti-tumor efficiency of various treatment methods (e.g., immunotherapy).…”
Get full text

SERS Platform Based on Bimetallic Au-Ag Nanowires-Decorated Filter Paper for Rapid Detection of miR-196ain Lung Cancer Patients Serum by Ji Xia, Yifan Liu, Menglin Ran, Dan Lu, Xiaowei Cao, Youwei Wang

“…Surface-enhanced Raman scattering (SERS) has achieved microRNA sensing for the diagnosis of primary liver cancers. In this work, we developed a SERS technology for the rapid detection of lung cancers-related miRNA (miR-196a) using bimetallic Au-Ag nanowire (AgNW@AuNPs) substrates coupled with the target hairpin DNA. …”
Get full text

Eco-friendly synthesis of chitosan NPs from Fioria vitifolia (L.) L: Potential to antibacterial, antioxidant, cytotoxicity properties of HepG2 cells and their evaluation of safety... by Mohamed Imath, Chinnasamy Ragavendran, Chinnaperumal Kamaraj, Ramalingam Karthik Raja, Gholamreza abdi

“…The aim of present study was examined antibacterial, antioxidant, antibiofilm and cytotoxicity of liver cancerous cells using Fioria vitifolia mediated chitosan nanoparticles (FV-CNPs). …”
Get full text

The Association Between Serum Gamma‐Glutamyl Transferase and Gastrointestinal Cancer Risk: A Systematic Review and Meta‐Analysis by Alireza Ramandi, Jacob George, Amir Hossein Behnoush, Alireza Delavari, Zahra Mohammadi, Hossein Poustchi, Reza Malekzadeh

“…The hazard ratio significance was also similar for Q3 (HR 1.22, 95% CI 1.15–1.30, p‐value < 0.001) and Q2 (HR 1.10, 95% CI 1.05–1.16, p‐value =0.002) of GGT. Colorectal and liver cancers showed a higher hazard ratio among Q2, Q3, and Q4 of GGT compared to Q1. …”
Get full text

Localized Drug Delivery in Different Gastrointestinal Cancers: Navigating Challenges and Advancing Nanotechnological Solutions by Hasan AM, Cavalu S, Kira AY, Hamad RS, Abdel-Reheim MA, Elmorsy EA, El-kott AF, Morsy K, AlSheri AS, Negm S, Saber S

“…Finally, the review discusses in detail the recent therapeutic and diagnostic applications of NDDs that have been conducted in oral, esophageal, gastric, colon, and liver cancers, aiming to offer valuable insights into the current and future state of utilizing NDDs for the local treatment of GI cancers. …”
Get full text